Obinutuzumab for cryoglobulinemia vasculitis after rituximab failure
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests if the drug obinutuzumab can help people with a blood vessel inflammation called cryoglobulinemia vasculitis when rituximab no longer works or causes side effects. It is a single-arm study, meaning everyone gets the new drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have active vasculitis (inflammation of blood vessels) from cryoglobulinemia.
- You must have tried rituximab and it either did not work well enough or you had to stop due to side effects.
- You must not have other reasons for vasculitis, active infections, or recent cancer.
- You must agree to use effective birth control if you could become pregnant, and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
This study compares two antibody medicines, obinutuzumab and rituximab, to prevent relapses of steroid-dependent or frequently relapsing nephrotic syndrome in children. It looks at whether one option works better and is safer, including infection risk.
This trial tests a medicine called obinutuzumab for people with lupus kidney disease (specifically class V membranous nephropathy) who have protein in their urine. The goal is to see if this treatment can reduce protein leakage and preserve kidney function.
This trial tests a medication called obinutuzumab to see if it can help people with systemic sclerosis (a disease that causes hardening of the skin and organs). It may reduce skin thickening and slow disease progression.
This study tests a new drug called obinutuzumab to see if it can keep nephrotic syndrome from coming back in adults who need repeated rituximab treatments. The goal is to see if obinutuzumab works better at controlling the disease compared to current care.
This trial tests whether obinutuzumab, a targeted therapy that quiets certain immune cells, can reduce kidney damage in people with fibrillary glomerulonephritis. If you have this rare kidney condition and significant protein in your urine, this study may offer a new treatment option.
Hear when a new Cryoglobulinemic Vasculitis (CV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.